
Argenx to acquire Forte for $2.2B to push FB102 as multi-disease autoimmune therapy
Argenx announced a $2.2 billion acquisition of Forte Biosciences to obtain FB102, a phase 1b anti-CD122 antibody that showed a 29.6% improvement in facial vitiligo and is set for phase 2 readouts in celiac disease later this year. The deal broadens Argenx’s autoimmune portfolio beyond Vyvgart and supports its Vision 2030 plan to reach 50,000 patients across 10 indications, financed by a strong cash position of about $5.2 billion. Forte shareholders will receive $77 per share.













